1. Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.
- Author
-
Yeo, Dannel, Huynh, Nhi, Beutler, John A., Baldwin, Graham S., He, Hong, and Nikfarjam, Mehrdad
- Subjects
- *
PANCREATIC cancer , *ANTINEOPLASTIC agents , *CANCER cells , *CELL lines , *ANIMAL models in research - Abstract
Background: Pancreatic cancer continues to have a poor survival rate with an urgent need for improved treatments. Glaucarubinone, a natural product first isolated from the seeds of the treeSimarouba glauca, has recently been recognized as having anti-cancer properties that may be particularly applicable to pancreatic cancer.Methods: The effect of glaucarubinone on the growth and migration of murine pancreatic cancer cells was assessed by3H-thymidine incorporation assay. The survival impact of glaucarubinone alone and in combination with gemcitabine chemotherapy was assessed using an immunocompetent orthotopic murine model of pancreatic cancer.Results: Glaucarubinone inhibited the growth of the murine pancreatic cancer cell lines LM-P and PAN02. Treatment with either glaucarubinone or gemcitabine reduced proliferationin vitroand the combination was synergistic. The combination treatment improved survival two-fold compared to gemcitabine treatment alone (p= 0.046) in PAN02 cells.Conclusions: The synergistic inhibition by glaucarubinone and gemcitabine observedin vitroand the improved survivalin vivosuggest that glaucarubinone may be a useful adjunct to current chemotherapy regimens. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF